Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110937 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Haoyu Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Institute of Respirato…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Sichuan University, Sichuan Province Science and Technology Support Program, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Current evidence suggests that C-reactive protein (CRP) levels may affect cancer prognosis. However, the effect of CRP has not been validated in immunotherapy recipients with non-small cell lung cancer (NSCLC). Therefore, we performed a meta-analysis to explore the prognostic value of CRP level in patients with NSCLC treated with immune checkpoint inhibitors. METHODS: PubMed, Web of Science, Embase, and Scopus databases were systematically retrieved for eligible publications, and hazard ratios (HRs) with corresponding 95% confidence intervals (95%CIs) were extracted and merged to evaluate the correlation between pretreatment CRP levels and overall survival (OS) and progression-free survival (PFS). Subgroup and sensitivity analyses were conducted to confirm these findings. RESULTS: Thirty-five cohorts consisting of 4698 patients were included in the primary analysis. Pooled results demonstrated that a higher pretreatment CRP level is associated with worse OS and PFS (OS: HR = 1.13, 95 %CI:1.09-1.18; PFS: HR = 1.16, 95 %CI:1.10-1.22). These findings remained robust after further statistical analyses. CONCLUSION: Pretreatment CRP level could be a promising biomarker for NSCLC immunotherapy. However, prospective studies are required to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Netw…
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
- Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
Förderung
- Sichuan University
- Sichuan Province Science and Technology Support Program
- National Natural Science Foundation of China
Zitieren
APA
Wang, H., Yang, R., Zhou, K., Wang, S., Cheng, C., Liu, D., & Li, W. (2023). Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110937
Vancouver
Wang H, Yang R, Zhou K, Wang S, Cheng C, Liu D, et al. Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110937
BibTeX
@article{Wang2023,
author = {Wang, Haoyu and Yang, Ruiyuan and Zhou, Ke and Wang, Suyan and Cheng, Cheng and Liu, Dan and Li, Weimin},
title = {Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110937}
}
EUVIMED